Immunoadsorption: Difference between revisions

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
m (→‎See also: link)
m (ref)
 
(67 intermediate revisions by the same user not shown)
Line 1: Line 1:
'''Immunoadsorption''' is the technique by which pathogenic substances, especially undesirable antibodies, are removed from blood plasma. It is considered to have fewer adverse effects than the use of therapeutic plasma exchange.<ref name="Pham, 2013"/> Several medical conditions, such as [[multiple sclerosis]]<ref> Koziolek, et al. Journal of Neuroinflammation (2012) 9:80. https://doi.org/10.1186/1742-2094-9-80</ref> and chronic inflammatory demyelinating polyneuropathy (CIDP)<ref>Lehmann, et al. Chapter 23 - Treatment of chronic inflammatory demyelinating polyradiculoneuropathy, Handbook of Clinical Neurology
'''Immunoadsorption''' or '''IA''' is an the technique by which [[immunoglobulin]]s, especially undesirable antibodies, are removed from blood [[plasma]]. '''Repeat Immunoadsorption''' or '''RIA''' involves a series of immunoadsorption treatments at fixed intervals.<ref name="Stein2013" /> Immonoadsorption is an [[apheresis]] treatment which has been investigated for [[ME/CFS]] and [[Long COVID]] patients.<ref name="Scheibenbogen2018" /><ref name="Stein2013" />
Volume 115, 2013, Pages 415-427, https://doi.org/10.1016/B978-0-444-52902-2.00023-0</ref> may use immunoadsorption as part of their medical regimen.


==Use in ME/CFS==
==Theory==
*2018, Immunoadsorption to remove ß2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME<ref>Scheibenbogen C, Loebel M, Freitag H, Krueger A, Bauer S, Antelmann M, et al. (2018) Immunoadsorption to remove ß2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME. PLoS ONE 13(3): e0193672. https://doi.org/10.1371/journal.pone.0193672</ref> [http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0193672 (Full Text)]
A number of studies have found that a subset of [[ME/CFS]] patients have abnormal autoantibodies in their blood; immunoadsorption could be used to remove these autoantibodies with the aim of improving symptoms or potentially curing [[ME/CFS]] in those patients.<ref name="Scheibenbogen2018" />
 
==Evidence==
A pilot study published before peer-review found Repeat Immunoadsorption was effective in improving ME/CFS symptoms in 10 patients with Long COVID who met the [[Canadian Consensus Criteria]] for ME/CFS, after developing ME/CFS after COVID-19 infection.<ref name="Stein2013" />
 
==Notable studies ==
*2023, Observational Study of Repeat Immunoadsorption (RIA) in Post-COVID ME/CFS Patients with Elevated Beta-2-Adrenergic Receptor Autoantibodies<ref name="Stein2013">{{Cite journal|title=Observational Study of Repeat Immunoadsorption (RIA) in Post-COVID ME/CFS Patients with Elevated Beta-2-Adrenergic Receptor Autoantibodies|date=2023-09-01|url=https://www.medrxiv.org/content/10.1101/2023.08.31.23294813v1|journal=medrxiv|pages=2023.08.31.23294813|last=Stein|first=Elisa|author-link=Elisa Stein|last2=Heindrich|first2=Cornelia|last3=Wittke|first3=Kirsten|last4=Kedor|first4=Claudia|last5=Kim|first5=Laura|last6=Freitag|first6=Helma|author-link6=Helma Freitag|last7=Krueger|first7=Anne|author-link7=Anne Krueger|last8=Toelle|first8=Markus|author-link8=Markus Toelle|last9=Scheibenbogen|first9=Carmen|author-link9=Carmen Scheibenbogen|language=en|doi=10.1101/2023.08.31.23294813}}</ref> - [https://doi.org/10.1101/2023.08.31.23294813 (Preprint - Full text)]
*2018, Immunoadsorption to remove ß2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME<ref name="Scheibenbogen2018">{{Cite journal | last = Scheibenbogen | first = Carmen | authorlink = Carmen Scheibenbogen | last2 = Loebel | first2 = Madlen | authorlink2 = Madlen Löbel | last3 = Freitag | first3 = Helma | authorlink3 = Helma Freitag | last4 = Krueger | first4 = Anne | authorlink4 =Anne Krueger | last5 = Bauer | first5 = Sandra | authorlink5 = Sandra Bauer | last6 = Antelmann | first6 = Michaela | authorlink6 = | last7 = Doehner | first7 = Wolfram | last8 = Scherbakov | first8 = Nadja | last9 = Heidecke | first9 = Harald | date = 2018-03-15 | title = Immunoadsorption to remove ß2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME | url = https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0193672|journal=PLOS ONE|language=en|volume=13|issue=3| pages = e0193672|doi=10.1371/journal.pone.0193672|issn=1932-6203|pmc=PMC5854315|pmid=29543914|access-date=|quote=|via=}}</ref> [http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0193672 (Full Text)]
 
==Clinicians==
 
==Risks and safety==
Immunoadsorption is considered to have fewer adverse effects than the use of therapeutic plasma exchange.<ref name="Pham, 2013">{{Cite book | last1 = Pham | first1 = H.P. | authorlink1 = | last2 = Schwartz | first2 = J. | authorlink2 = | title = Transfusion medicine and hemostasis: clinical and laboratory aspects.| date = 2013 | pmid = | doi = 10.1016/B978-0-12-397164-7.00079-3|url= | pages = 525–527|chapter=79 - Immunoadsorption|edition=2|isbn=|location=Newnes|editor-last = Shaz|editor-first = B. H.|editor2-last = Hillyer|editor2-first = C.D.}}</ref> Several medical conditions, such as [[multiple sclerosis]]<ref name="Koziolek2018">{{Cite journal | last = Koziolek | first = Michael J. | last2 = Tampe | first2 = Desiree | last3 = Bähr | first3 = Matthias | last4 = Dihazi | first4 = Hassan | last5 = Jung | first5 = Klaus | last6 = Fitzner | first6 = Dirk | last7 = Klingel | first7 = Reinhard | last8 = Müller | first8 = Gerhard A. | last9 = Kitze | first9 = Bernd | date = 2012-04-26 | title = Immunoadsorption therapy in patients with multiple sclerosis with steroid-refractory optical neuritis | url = https://doi.org/10.1186/1742-2094-9-80|journal=Journal of Neuroinflammation|volume=9|issue=1 | pages = 80|doi=10.1186/1742-2094-9-80|issn=1742-2094|pmc=PMC3418188|pmid=22537481}}</ref> and chronic inflammatory demyelinating polyneuropathy (CIDP) may use immunoadsorption as part of their medical regimen.<ref name="Lehmann2013">{{Cite book | last = Lehmann | first = Helmar C. | authorlink = | last2 = Hughes | first2 = Richard A.C. | authorlink2 = | last3 = Hartung | first3 = Hans-Peter | authorlink3 = | date = 2013-01-01|editor-last = Said|editor-first = Gérard|editor2-last = Krarup|editor2-first = Christian | title = Handbook of Clinical Neurology. | url = https://www.sciencedirect.com/science/article/pii/B9780444529022000230|chapter=23 - Treatment of chronic inflammatory demyelinating polyradiculoneuropathy|work=Peripheral Nerve Disorders|language=en|publisher=Elsevier|volume=115|series=3 | pages = 415–427|doi=10.1016/b978-0-444-52902-2.00023-0|pmc=|pmid=|quote=|via=}}</ref>
 
==Costs and availability==


==Learn more==
==Learn more==
*[https://en.wikipedia.org/wiki/Immunoadsorption Wikipedia page for Immunoadsorption]
*[https://en.wikipedia.org/wiki/Immunoadsorption Wikipedia]
*2018, [http://simmaronresearch.com/2018/04/hope-mecfs-autoimmune-subset-german-researcher-steps-forward/ Hope for an ME/CFS Autoimmune Subset: A German Researcher Steps Forward] ([[Carmen Scheibenbogen]])
*2018, [http://simmaronresearch.com/2018/04/hope-mecfs-autoimmune-subset-german-researcher-steps-forward/ Hope for an ME/CFS Autoimmune Subset: A German Researcher Steps Forward] ([[Carmen Scheibenbogen]])


==See also==
==See also==
*[[Autoimmune hypothesis]]
*[[Autoimmune hypothesis]]
*[[Autoantibody]]
*[[Carmen Scheibenbogen]]
*[[Carmen Scheibenbogen]]


==References==
==References==
<references>
{{Reflist}}
<ref name="Pham, 2013">
{{Citation
| last1  = Pham              | first1 = Huy P.            | authorlink1 =
| last2  = Schwartz          | first2 = Joseph            | authorlink2 =
| title  = Chapter 79 – Immunoadsorption
| journal =  Transfusion Medicine and Hemostasis  | volume =    | issue =    | page = 525–527
| date    = 2013
| pmid    =
| doi    = 10.1016/B978-0-12-397164-7.00079-3
}}
</ref>
</references>


[[Category:Potential treatments]]
[[Category:Potential treatments]]
[[Category:Immunomodulators‎]]
[[Category:Immunostimulants‎]]
[[Category:Apheresis‎]]

Latest revision as of 13:01, September 2, 2023

Immunoadsorption or IA is an the technique by which immunoglobulins, especially undesirable antibodies, are removed from blood plasma. Repeat Immunoadsorption or RIA involves a series of immunoadsorption treatments at fixed intervals.[1] Immonoadsorption is an apheresis treatment which has been investigated for ME/CFS and Long COVID patients.[2][1]

Theory[edit | edit source]

A number of studies have found that a subset of ME/CFS patients have abnormal autoantibodies in their blood; immunoadsorption could be used to remove these autoantibodies with the aim of improving symptoms or potentially curing ME/CFS in those patients.[2]

Evidence[edit | edit source]

A pilot study published before peer-review found Repeat Immunoadsorption was effective in improving ME/CFS symptoms in 10 patients with Long COVID who met the Canadian Consensus Criteria for ME/CFS, after developing ME/CFS after COVID-19 infection.[1]

Notable studies[edit | edit source]

  • 2023, Observational Study of Repeat Immunoadsorption (RIA) in Post-COVID ME/CFS Patients with Elevated Beta-2-Adrenergic Receptor Autoantibodies[1] - (Preprint - Full text)
  • 2018, Immunoadsorption to remove ß2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME[2] (Full Text)

Clinicians[edit | edit source]

Risks and safety[edit | edit source]

Immunoadsorption is considered to have fewer adverse effects than the use of therapeutic plasma exchange.[3] Several medical conditions, such as multiple sclerosis[4] and chronic inflammatory demyelinating polyneuropathy (CIDP) may use immunoadsorption as part of their medical regimen.[5]

Costs and availability[edit | edit source]

Learn more[edit | edit source]

See also[edit | edit source]

References[edit | edit source]

  1. 1.0 1.1 1.2 1.3 Stein, Elisa; Heindrich, Cornelia; Wittke, Kirsten; Kedor, Claudia; Kim, Laura; Freitag, Helma; Krueger, Anne; Toelle, Markus; Scheibenbogen, Carmen (September 1, 2023). "Observational Study of Repeat Immunoadsorption (RIA) in Post-COVID ME/CFS Patients with Elevated Beta-2-Adrenergic Receptor Autoantibodies". medrxiv: 2023.08.31.23294813. doi:10.1101/2023.08.31.23294813.
  2. 2.0 2.1 2.2 Scheibenbogen, Carmen; Loebel, Madlen; Freitag, Helma; Krueger, Anne; Bauer, Sandra; Antelmann, Michaela; Doehner, Wolfram; Scherbakov, Nadja; Heidecke, Harald (March 15, 2018). "Immunoadsorption to remove ß2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME". PLOS ONE. 13 (3): e0193672. doi:10.1371/journal.pone.0193672. ISSN 1932-6203. PMC 5854315. PMID 29543914.
  3. Pham, H.P.; Schwartz, J. (2013). "79 - Immunoadsorption". In Shaz, B. H.; Hillyer, C.D. (eds.). Transfusion medicine and hemostasis: clinical and laboratory aspects (2 ed.). Newnes. pp. 525–527. doi:10.1016/B978-0-12-397164-7.00079-3.
  4. Koziolek, Michael J.; Tampe, Desiree; Bähr, Matthias; Dihazi, Hassan; Jung, Klaus; Fitzner, Dirk; Klingel, Reinhard; Müller, Gerhard A.; Kitze, Bernd (April 26, 2012). "Immunoadsorption therapy in patients with multiple sclerosis with steroid-refractory optical neuritis". Journal of Neuroinflammation. 9 (1): 80. doi:10.1186/1742-2094-9-80. ISSN 1742-2094. PMC 3418188. PMID 22537481.
  5. Lehmann, Helmar C.; Hughes, Richard A.C.; Hartung, Hans-Peter (January 1, 2013). "23 - Treatment of chronic inflammatory demyelinating polyradiculoneuropathy". In Said, Gérard; Krarup, Christian (eds.). Handbook of Clinical Neurology. Peripheral Nerve Disorders. 3. 115. Elsevier. pp. 415–427. doi:10.1016/b978-0-444-52902-2.00023-0.